Immunome, Inc. (NasdaqCM:IMNM) entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS) for $94.2 million on February 5, 2024. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval.

A.G.P./Alliance Global Partners is acting as Financial advisor to Ayala Pharmaceuticals, Inc. in connection with the transaction.